Abstract
Secukinumab is a novel fully human monoclonal antibody directed against interleukin-17A, one of the most important cytokines involved in the pathogenesis of psoriasis. The efficacy and safety of secukinumab has been assessed in several randomized phase III clinical trials which demonstrated its superiority over placebo (ERASURE, JUNCTURE, FEATURE trials), etanercept (FIXTURE trial) as well as ustekinumab (CLEAR trial).
Long-term extensions of ERASURE, FIXTURE a SCULPTURE trials show that the efficacy of secukinumab is sustained over 2 and 3 years. Secukinumab administration is usually well tolerated with upper respiratory tract infections being the most common adverse events in clinical trials.